Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K2GV
|
|||
| Former ID |
DIB013426
|
|||
| Drug Name |
HIV vaccine
|
|||
| Synonyms |
HIVA vaccine, Oxford University/Nairobi University; HIV vaccine (prophylactic, DNA/MVA prime-boost); HIV vaccine (prophylactic, Prime-Boost), Oxford University; HIV-1 clade A gag p24/p17 vaccine, Oxford University/Nairobi University; HIVA DNA/MVA vaccine (AIDS), Oxford University/Nairobi University; HIVA DNA/MVA vaccine (HIV), Oxford University/Nairobi University; MVA HIV vaccine (prophylactic, Prime-Boost), Oxford University; Modified vaccinia Ankara (MVA) HIV vaccine (prophylactic, Prime-Boost), Oxford University; HIV subtype A vaccine (prophylactic, DNA/MVA prime-boost), Oxford University/Nairobi University; HIV vaccine (prophylactic, DNA/MVA prime-boost), Oxford University/Nairobi University; HIV-1 vaccine (prophylactic, DNA/MVA prime-boost), Oxford University/Nairobi University
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
GeoVax Labs; GlaxoSmithKline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of GeoVax. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.